Helgi van de Velde

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Bin Jiang, Ofer Shpilberg, D. Esseltine, 2008, The New England journal of medicine.

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.

Eugene Zhu, Shalini Chaturvedi, H. Eom, 2015, Blood.

Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.

Muriel Viala, D. Esseltine, D. Dubois, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution

Franziska Michor, Michael H. Tomasson, Irene M. Ghobrial, 2016, Clinical Cancer Research.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Bin Li, Matthew Schu, R. Neuwirth, 2014, Blood.